VFA
VRTX icon

Voya Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Voya Financial Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-903
Closed -$210K – 691
2020
Q4 		$210K Sell
903
-200
-18% -$45.9K 0.01% 597
2020
Q3 		$298K Buy
1,103
+171
+18% +$47.2K 0.01% 472
2020
Q2 		$266K Buy
+932
New +$253K 0.01% 494

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Voya Financial Advisors's VRTX Position: Q1 2021 in Review

Voya Financial Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2021, closing a stake of 903 shares — an estimated $210K sold.

Voya Financial Advisors first reported a position in VRTX in Q2 2020 and held it in 3 quarters. The position peaked at $298K in Q3 2020. 1,000 funds tracked by Wall St. Rank hold VRTX as of Q1 2021.

  • Voya Financial Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Voya Financial Advisors sold 903 Vertex Pharmaceuticals shares in Q1 2021, an estimated $210K.
  • Voya Financial Advisors first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Voya Financial Advisors's Vertex Pharmaceuticals position peaked at $298K in Q3 2020.
  • 1,000 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2021.

Based on Voya Financial Advisors's 13F filing for Q1 2021, filed 17 May 2021.